Errata (DOI:10.1016/S1470-2045(06)70729-X);Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma

Lancet Oncology

Volumn 7, Issue 6, 2006, Pages 521-523

  Azizi, Amedeo A ^a   Haberler, Christine ^b   Czech, Thomas ^a   Gupper, Astrid ^a   Prayer, Daniela ^a   Breitschopf, Helene ^a   Acker, Till ^c   Slavc, Irene ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBAMAZEPINE; DACTINOMYCIN; DOXORUBICIN; IFOSFAMIDE; THALIDOMIDE; VALPROIC ACID; VASCULOTROPIN; VINCRISTINE;

ALVEOLAR SOFT PART SARCOMA; ARTICLE; ATAXIA; BOY; BRAIN METASTASIS; BRAIN TUMOR; CANCER GROWTH; CASE REPORT; CEREBELLUM; COMPUTER ASSISTED TOMOGRAPHY; CONVULSION; CYST FLUID; DRUG DOSE REGIMEN; GRAND MAL SEIZURE; HEADACHE; HEMIANOPIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; INTRACRANIAL HYPERTENSION; LUNG METASTASIS; MALE; METASTASIS POTENTIAL; MOTOR DYSFUNCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; PAPILLEDEMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; TUMOR CELL; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

EID: 33646896306     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)70740-9     Document Type: Erratum

References (15)

1. Reichardt P., Lindner T., Pink D., et al. Chemotherapy in alveolar soft part sarcomas. What do we know?. Eur J Cancer 39 (2003) 1511-1516
2. Therasse P., Arbuck S., Eisenhauer E., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
3. Marler J., Rubin J., Trede N., et al. Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. Pediatrics 109 (2002) E37
4. Beecken W., Fernandez A., Joussen A., et al. Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice. J Natl Cancer Inst 93 (2001) 382-387
5. Jain R. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19 suppl 3 (2005) 7-16
6. Liekens S., De Clercq E., and Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 61 (2001) 253-270
7. Folkman J. Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther 2 (2003) S127-S133
8. Lenz H. Antiangiogenic agents in cancer therapy. Oncology (Williston Park) 19 suppl 3 (2005) 17-25
9. Kuriyama K., Todo S., Hibi S., et al. Alveolar soft part sarcoma with lung metastases. Response to interferon alpha-2a?. Med Pediatr Oncol 37 (2001) 482-483
10. Roozendaal K., de Valk B., ten Velden J., et al. Alveolar soft-part sarcoma responding to interferon alpha-2b. Br J Cancer 89 (2003) 243-245
11. Bisogno G., Rosolen A., and Carli M. Interferon alpha for alveolar soft part sarcoma. Pediatr Blood Cancer 44 (2005) 687-688
12. Hicklin D., and Ellis L. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 (2005) 1011-1027
13. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25 (2004) 581-611
14. Pichelmayer O., Zielinski C., and Raderer M. Response of a nonmalignant pleural effusion to bevacizumab. N Engl J Med 353 (2005) 740-741
15. Casanovas O., Hicklin D., Bergers G., and Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8 (2005) 299-309